Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Catyalyst Pharmaceutical (CPRX) Posts Q3 Loss of 6c/Share
November 14, 2014 8:05 AM ESTCatyalyst Pharmaceutical (NASDAQ: CPRX) reported Q3 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05).
For earnings history and earnings-related data on Catyalyst Pharmaceutical (CPRX) click here.
... More